S1048
Clinical – Sarcoma, skin cancer, malignant melanoma
ESTRO 2026
reflecting heterogeneity in patient selection, disease stage, and treatment sequencing. The temporal dimension of STS management therefore remains an unresolved aspect of oncologic care. This study aimed to evaluate whether the interval between diagnostic biopsy and definitive surgery impacts disease-free survival (DFS) in patients with limb or trunk STS treated with neoadjuvant radiotherapy (RT). Material/Methods: We conducted a retrospective single-centre cohort study at the Centre Léon Bérard (Lyon, France). Adult patients ( ≥ 18 years) with primary, non-metastatic limb or trunk STS treated between 2010 and 2020, with normofractionated neoadjuvant RT (50 Gy in 25 fractions) followed by curative-intent surgery were included. The biopsy-to-surgery interval was analysed both as a continuous variable (per +30 days) and by quartiles. The primary endpoint was DFS, defined from surgery to local or distant recurrence or death. Univariable and multivariable analyses were performed, adjusting for key clinical and pathological factors (age, sex, tumour size, FNCLCC grade, site, ECOG performance status, and neoadjuvant chemotherapy). Results:
Only 13 of 36 studies scored ≥ 70% on MMAT. Most studies focused on people with breast cancer (n=25). Reporting of ethnicity and skin tone was inconsistent; only nine studies used the Fitzpatrick scale, though often without baseline skin tone documentation. Significant variability and inconsistency existed in how skin tone was assessed. Twelve studies relied on clinician/researcher observation of skin tone while ten studies failed to report any method. CTCAE and RTOG were used in 34 studies, CTCAE alone in 17 studies and RTOG alone in 17 studies. Despite including people of colour, studies most used erythema (n=20), pigmentation (n=8), redness (n=6) and darker/darkening (n=5). Non-visual symptoms (pain, pruritus, burning) were reported in three studies but lacked validated tools to ensure credibility. PROMS were inconsistently used and not adapted for skin of colour. Only one study highlighted a wide range of descriptors for black, brown and white skin tones while advocating for non-visual cues for diagnosis RISR and providing patient images of RISR in different skin tones to aid assessment. Conclusion: Current RISR assessment approaches inadequately capture toxicities in people of colour. Standardising skin tone reporting for detection of RISR by developing and validating multimodal RISR tools in people of different skin tones is urgently needed. These need to include culturally adapted PROMS, visual, non- visual, and objective measures
to ensure equitable assessment of RISR. Keywords: Radiation Dermatitis, Equity
Digital Poster 4007
Association between biopsy-to-surgery interval and disease-free survival in soft-tissue sarcoma treated with neoadjuvant radiotherapy Frederic Carlet 1,2 , Waisse Waissi 1 , Amine Bouhamama 3 , Gualter Vaz 4 , François Gouin 4 , Mehdi Brahmi 5 , Marie- Pierre Sunyach 1 , Jean-Yves Blay 5 , Benoît Allignet 1,6 1 Department of Radiation Oncology,, Centre Leon Bérard, Lyon, France. 2 Department of Radiation Oncology, CHU de Saint-Etienne, Saint-Etienne, France. 3 Department of Radiology, Centre Léon Bérard, Lyon, France. 4 Department of Surgical Oncology, Centre Leon Bérard, Lyon, France. 5 Department of Medical Oncology, Centre Leon Bérard, Lyon, France. 6 CREATIS UMR 5220, U1294, Université Claude Bernard Lyon 1, Villeurbanne, France Purpose/Objective: The prognostic implications of treatment delays in soft-tissue sarcoma (STS) remain uncertain. Previous studies have reported conflicting associations between treatment intervals and survival outcomes, likely
Made with FlippingBook - Share PDF online